阿尔茨海默病认知能力的性别差异:来自ADAS-Cog-13的见解
medRxiv : the preprint server for health sciences
|July 17, 2025
概括
性差异对阿尔茨海默病 (AD) 的认知测试产生影响. 女性在正常认知中的某些认知评估中表现更好,而男性在阿兹海默症患者中延迟回忆方面表现更好.
科学领域:
- 神经学 神经学
- 神经心理学 神经心理学
- 老年学是指老年学的学科.
背景情况:
- 在阿尔茨海默病 (AD) 中确立了性别差异.
- 性对认知评估工具的影响尚未完全理解.
- 痴呆症评估尺度-认知子尺度 (ADAS-Cog-13) 是评估认知功能的关键工具.
研究的目的:
- 用ADAS-Cog-13来调查基于性别的认知表现差异.
- 分析这些差异在认知正常 (CN) 个体和AD个体.
- 了解对解释认知测试结果的影响.
主要方法:
- 在ADAS-Cog-13得分中分析性别差异.
- 参与者的分层分为认知正常和AD组.
- 控制海马缩作为一个混因素.
主要成果:
- 在认知上正常的女性在ADAS-Cog-13总分,单词回忆,命名和单词识别方面表现优于男性.
- 在阿兹海默症患者的ADAS-Cog-13总得分中没有发现任何显著的性别差异.
- 与AD女性相比,AD男性在延迟的单词回忆方面表现优越.
结论:
- 在解释认知测试结果时,应考虑性别,特别是ADAS-Cog-13.
- 认知评估可能会揭示性别特异性的模式,特别是在阿尔茨海默病的早期阶段.
- 这些发现强调了性别作为AD研究和临床实践中的生物变量的重要性.
相关概念视频
Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
Cognitive Development During Adulthood
289
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
289
Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263
Dementia
169
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
169
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
212
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
212


